FDA Limits Use of Nizoral Tablets and Warns of Potential for Fatal Injuries
The FDA issued a safety warning related to the use of oral Nizoral (ketoconazole) tablets for the treatment of fungal infections. The agency warns that use of Nizoral tablets can cause severe liver injuries and adrenal gland problems. It cautions that patients taking high doses of Nizoral for short periods of time, as well as those taking low doses for longer periods can suffer liver injury or disease. Nizoral tablets can also negatively impact a patient’s adrenal glands and cause a serious electrolyte imbalance.
Topical formulations of Nizoral have not been associated with liver or adrenal gland problems. Nizoral tablets can be prescribed to treat fungal infections and conditions such as thrush, athlete’s foot, dandruff, and ringworm.
The FDA warns that oral Nizoral use should be limited and used for treatment of fungal infections only when alternative therapies are not available. It also warns against using Nizoral tablets for patients with acute or chronic liver disease. The safety announcement which includes the warnings and limitations for this drug can be found on the FDA website.
If you or someone you care about has taken Nizoral tablets and suffered a serious injury, contact us. Our product liability attorneys have litigated thousands of product liability claims against pharmaceutical companies and medical device manufacturers and can advise you of your legal rights and options.
